Tumour necrosis factor-α and soluble Fas ligand as biomarkers in non-acetaminophen-induced acute liver failure

References

• Acharya SK, Dasarathy S, Kumer TL, Sushma S, Prasanna KS, Tandon A, Sreenivas V, Nijhawan S, Panda SK, Nanda SK, Irshad M, Joshi YK, Duttagupta S, Tandon RK, Tandon BN. (1996). Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 23:1448–55.
   PubMed Web of Science ®Google Scholar
• Acharya SK, Panda SK, Saxena A, Gupta SD. (2000). Acute hepatic failure in India: a perspective from the East. J Gastroenterol Hepatol 15:473–9.
   PubMed Web of Science ®Google Scholar
• Bernuau J, Rueff B, Benhamou JP. (1986). Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 6:97–106.
   PubMed Web of Science ®Google Scholar
• Bhatia V, Singhal A, Panda SK, Acharya SK. (2008). A 20-year single-center experience with acute liver failure during pregnancy: is the prognosis really worse? Hepatology 48:1577–85.
   PubMed Web of Science ®Google Scholar
• De la Mata M, Meager A, Rolando N, Daniels HM, Nouri-Aria KT, Goka AK, Eddleston AL, Alexander GJ, Williams R. (1990). Tumour necrosis factor production in fulminant hepatic failure: relation to aetiology and superimposed microbial infection. Clin Exp Immunol 82:479–84.
   PubMed Web of Science ®Google Scholar
• Dhiman RK, Seth AK, Jain S, Chawla YK, Dilawari JB. (1998). Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci 43:1311–16.
   PubMedGoogle Scholar
• Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L. (1995). Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182:1223–30.
   PubMed Web of Science ®Google Scholar
• Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. (2002). Mechanisms of hepatotoxicity. Toxicol Sci 65:166–76.
   PubMed Web of Science ®Google Scholar
• Kar P, Budhiraja S, Narang A, Chakravarthy A. (1997). Etiology of sporadic acute and fulminant non-A, non-B viral hepatitis in north India. Indian J Gastroenterol 16:43–5.
   Google Scholar
• Kasahara I, Saitoh K, Nakamura K. (2000). Apoptosis in acute hepatic failure: histopathological study of human liver tissue using the tunel method and immunohistochemistry. J Med Dent Sci 47:167–75.
   Google Scholar
• Lidofsky SD, Bass NM, Prager MC, Washington DE, Read AE, Wright TL, Ascher NL, Roberts JP, Scharschmidt BF, Lake JR. (1992). Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 16:1–7.
   PubMed Web of Science ®Google Scholar
• Nagaki M, Iwai H, Naiki T, Ohnishi H, Muto Y, Moriwaki H. (2000). High levels of serum interleukin-l0 and tumor necrosis factor-α are associated with fatality in fulminant hepatitis. J Infect Dis 182:1103–08.
   PubMedGoogle Scholar
• Mita A, Hashikura Y, Tagawa Y, Nakayama J, Kawakubo M, Miyagawa S. (2005). Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure. Am J Gastroenterol 100:2551–9.
   Google Scholar
• Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. (1988). Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 9:72–4.
   Google Scholar
• Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364:806–9.
   PubMed Web of Science ®Google Scholar
• O’Grady JG, Alexander GJ, Hayllar KM, Williams R. (1989). Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97:439–45.
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM; US Acute Liver Failure Study Group. (2002). Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947–54.
   PubMed Web of Science ®Google Scholar
• Rivero M, Crespo J, Fábrega E, Casafont F, Mayorga M, Gomez-Fleitas M, Pons-Romero F. (2002). Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat 9:107–13.
   PubMed Web of Science ®Google Scholar
• Rust C, Gores GJ. (2000). Apoptosis and liver disease. Am J Med 108:567–74.
   PubMed Web of Science ®Google Scholar
• Rutherford A, Hynan LS, Borges CB, Forcione DG, Blackard JT, Lin W, Gorman AR, Shaikh OS, Reuben A, Harrison E, Reddy KR, Le WM, Chung RT; ALF Study Group. (2007). Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol 5:1477–83.
   PubMed Web of Science ®Google Scholar
• Ryo K, Kamogawa Y, Yamauchi K, Hayashi N. (1996). Involvement of Fas and Fas ligand in case of human fulminant hepatitis. Nippon Rinsho 54:1965–9.
   Google Scholar
• Ryo K, Kamogawa Y, Ikeda I, Yamauchi K, Yonehara S, Nagata S, Hayashi N (2000). Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 95:2047–55.
   Google Scholar
• Sallie R, Silva AE, Purdy M, Smith H, McCaustland K, Tibbs C, Portmann B, Eddleston A, Bradley D, Williams R. (1994). Hepatitis C and E in non-A non-B fulminant hepatic failure: a polymerase chain reaction and serological study. J Hepatol 20:580–8.
   PubMedGoogle Scholar
• Schiodt FV, Atillasoy E, Shakil AO, Schiff ER, Caldwell C, Kowdley KV, Stribling R, Crippin JS, Flamm S, Somberg KA, Rosen H, McCashland TM, Hay JE, Lee WM. (1999). Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 5:29–34.
   PubMedGoogle Scholar
• Sekiyama KD, Yoshiba M, Thomson AW. (1994). Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 98:71–7.
   PubMed Web of Science ®Google Scholar
• Singhal S, Jain S, Kohaar I, Singla M, Gondal R, Kar P. (2008). Apoptotic mechanisms in fulminant hepatic failure: potential therapeutic target. Appl Immunohistochem Mol Morphol Dec 11 [Epub ahead of print].
   Google Scholar
• Smedile A, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, Dentico P, Trepo C, Opolon P, Gimson A, Vergani D, Williams R, Rizzetto M. (1982). Influence of delta infection on severity of Hepatitis B. Lancet 2:945–7.
   PubMed Web of Science ®Google Scholar
• Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, Brenner D, Manns M, Trautwein C. (2000). Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 119:446–60.
   PubMed Web of Science ®Google Scholar
• Tandon BN, Bernauau J, O’Grady J, Gupta SD, Krisch RE, Liaw YF, Okuda K, Acharya SK. (1999). Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. J Gastroenterol Hepatol 14:403–4.
   PubMed Web of Science ®Google Scholar
• Tokushige K, Yamaguchi N, Ikeda I, Hashimoto E, Yamauchi K, Hayashi N. (2000). Significance of soluble TNF receptor-I in acute-type fulminant hepatitis. Am J Gastroenterol 95:2040–6.
   Google Scholar
• Trey C, Davidson CS. (1970). The management of fulminant hepatic failure. Prog Liver Dis 3:282–98.
   PubMedGoogle Scholar
• Vickers C, Neuberger J, Buckels J, McMaster P, Elias E. (1988). Transplantation of the liver in adults and children with fulminant hepatic failure. J Hepatol 7:143–50.
   Google Scholar
• Wang JY, Wang XL, Liu P. (1999). Detection of serum TNF-alpha, IFN-beta, IL-6 and IL-8 in patients with hepatitis B. World J Gastroenterol 5:38–40.
   Google Scholar